Interleukin-2 is a potent latency reversal agent in people with treated HIV-1
Science Advances · 2025
DOI: 10.1126/sciadv.aea4268 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Michael L Freeman und 10 weiteren Autor:innen. Beteiligte Einrichtung: Rustbelt Center for AIDS Research, Case Western Reserve University, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Interleukin-2, HIV-1, HIV Infections, Virus Latency. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
Eliciting HIV-1 expression from latently infected CD4 + T cells allows these rare reservoir cells to become targets of the immune system and may also result in death of reservoir cells via virus-induced cytopathy. We asked whether administration of recombinant interleukin-2 (rIL-2) to people with HIV-1 (PWH) on antiretroviral therapy (ART) would induce HIV-1 replication and activate cellular immunity. Nine men with ART-suppressed HIV-1 completed a single 4-day cycle of rIL-2 administration. Plasma HIV-1 RNA levels rose from
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Rustbelt Center for AIDS Research, Case Western Reserve University, Cleveland, OH, USA.
- Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
- Center for Global Health and Diseases, Department of Pathology, Case Western Reserve University, Cleveland, OH, USA.
- Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, OH, USA.
- Accelevir Diagnostics, Baltimore, MD, USA.
ORCID-Profile: Michael L Freeman, Brian M Clagett, Konstantin Leskov, Scott F Sieg, Gregory M Laird, Jonathan Karn, Jeffrey M Jacobson, Michael M Lederman
Förderung
- Gilead Sciences
Zitieren
APA
Freeman, M. L., Clagett, B. M., Leskov, K., Moisi, D., Yendewa, G. A., Sieg, S. F., Laird, G. M., Karn, J., Jacobson, J. M., Rodriguez, B., & Lederman, M. M. (2025). Interleukin-2 is a potent latency reversal agent in people with treated HIV-1. Science Advances. https://doi.org/10.1126/sciadv.aea4268
Vancouver
Freeman ML, Clagett BM, Leskov K, Moisi D, Yendewa GA, Sieg SF, et al. Interleukin-2 is a potent latency reversal agent in people with treated HIV-1. Science Advances. 2025. doi:10.1126/sciadv.aea4268
BibTeX
@article{Freeman2025,
author = {Freeman, Michael L and Clagett, Brian M and Leskov, Konstantin and Moisi, Daniela and Yendewa, George A and Sieg, Scott F and Laird, Gregory M and Karn, Jonathan and Jacobson, Jeffrey M and Rodriguez, Benigno and Lederman, Michael M},
title = {Interleukin-2 is a potent latency reversal agent in people with treated HIV-1},
journal = {Science Advances},
year = {2025},
doi = {10.1126/sciadv.aea4268}
}
EUVIMED